



## NEW WARRANT PLAN APPROVED BY MITHRA SHAREHOLDERS

**Liège, Belgium, 06 November 2018 – 7:30 CET** – Mithra (Euronext Brussels: MITRA), a company specialized in Women's Health, today announces that shareholders have approved the issuance of a maximum of 1,881,974 warrants under a new warrant plan ('Warrant Plan'), for the benefit of key employees, members of the management team and certain directors. The Warrant Plan was approved at the Company's Extraordinary General Meeting (EGM) held on 5 November 2018.

The warrants have a longevity period of five years as of the date of issuance. They are generally not transferable and can, in principle, not be exercised prior to the date of the grant's second anniversary (i.e. 6 November 2020). The warrants are subject to vesting conditions.

Each warrant gives the right to subscribe to one new Mithra share. Should the warrants be exercised, Mithra will apply for the listing of the resulting new shares on Euronext Brussels. The warrants as such will not be listed on any stock exchange market.

Mithra's total share capital currently amounts to EUR 27,555,760.70 divided in 37,639,495 shares of the same category. As of today, some 650 warrants representing 1,072,500 new shares are yet to be exercised as from 1 January 2019, pursuant to a previous warrant plan granted by Mithra in March 2015.

\*\*\*\*\*

### For more information, please contact:

#### Investor Relations & Press

**François Fornieri (CEO):** +32 4 349 28 22

**Jean-Manuel Fontaine (PRO):** +32 (0)476 96 54 59

[investorrelations@mithra.com](mailto:investorrelations@mithra.com)

### About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: [www.mithra.com](http://www.mithra.com)

### Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

To subscribe to Mithra's newsletter, visit [investors.mithra.com](https://investors.mithra.com)